Medical News

RSS

UKONS publishes position statement on safe, effective use of oral anticancer medicines

A position statement from the UK Oncology Nursing Society (UKONS) on the safe, effective use of oral anticancer medicines was published online on 5 February 2010 by ecancermedicalscience.

17 Feb 2010

OTRC: Secondhand smoke exposure is a serious health hazard

New research by the Oklahoma Tobacco Research Center (OTRC) shows that concentrations of secondhand tobacco smoke inhaled in smoking rooms of restaurants and bars are exceptionally high and hazardous to health.

17 Feb 2010

AHF to protest Merck’s Isentress pricing and policies at CROI

AIDS Healthcare Foundation (AHF) will host a protest Wednesday morning, February 17 at 8:00am targeting Merck and Co. Pharmaceuticals over the pricing and policies for its key HIV/AIDS drug, Isentress, the most expensive first-line AIDS treatment in the US, during the 17th Conference of Retroviruses and Opportunistic Infections (CROI) in San Francisco.

17 Feb 2010

Purdue officials report double-digit increases in research funding

Richard O. Buckius, Purdue's vice president for research, reported a record $342.2 million in sponsored research programs for fiscal year 2008-09. That represents an 18 percent increase in federal support and a 2.2 percent increase in industry research support from the previous year.

17 Feb 2010

CDA, OneAmerica Financial Partners to educate American workforce on disability planning

The Council for Disability Awareness (CDA) is pleased to announce that OneAmerica Financial Partners, Inc. has joined the CDA to help raise awareness about the importance of disability planning and prevention.

17 Feb 2010

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Research published in February's edition of the Journal of Thoracic Oncology investigates the utilization of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC). Traditionally, SCLC treatment regimes include chemotherapy and radiotherapy for limited stage disease; however, the study concludes that in selected patients with early stage disease a lobectomy (removal of lung) had an excellent overall survival without additional treatment.

17 Feb 2010

Low-income nations lack advanced e-health tools that can help them achieve better health outcomes

In an essay in the February 2010 issue of Health Affairs, a special issue of the journal devoted to global e-health, William Tierney, M.D., of Indiana University School of Medicine and the Regenstrief Institute, and colleagues, who like Dr. Tierney have significant experience in the development of workable health information technology systems in low-income countries, identify critical steps toward allowing developing countries to cross the "digital divide" to realize the full potential of e-health to improve the quality and efficiency of their health care systems.

17 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

Novel composite foam could lead to new generation of biomedical implants

A "metal foam" that has a similar elasticity to bone could mean a new generation of biomedical implants that would avoid bone rejection that often results from more rigid implant materials, such as titanium.

17 Feb 2010

LUMEDX completes extensive cardiovascular PACS deployment at IHS

LUMEDX Corporation, a leading provider of vendor-agnostic, integrated medical imaging and information systems, announced the completion of an extensive cardiovascular PACS deployment at Iowa Health Systems (IHS). Working together with IHS, a team of technical and clinical experts implemented CardioPACS multi-modality imaging system at ten affiliate hospitals across Iowa and western Illinois in under six months’ time. The first site, Trinity Regional Medical Center in Fort Dodge, went live July 3, 2009; by December 16, all ten sites were using CardioPACS.

17 Feb 2010

Researchers find food safety violations in independently owned ethnic restaurants in Kansas

In a study of independently owned restaurants in 14 Kansas counties, Kansas State University researchers found a significantly higher number of food safety violations in ethnic restaurants than in nonethnic restaurants. The next step for their research is to understand the reasons for these differences and to work alongside restaurant operators to remedy the problems.

17 Feb 2010

AMAG's Feraheme use on the rise

BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.

17 Feb 2010

Researchers discover new strategy to overcome drug resistance in breast cancer

Combining tamoxifen, the world's most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

17 Feb 2010

ICAP Ocean Tomo offers Medcanica's patent portfolio for sale

ICAP Ocean Tomo, the intellectual property brokerage division of ICAP plc (IAP.L), is offering for sale a patent portfolio relating to a cardiothoracic surgery system owned by Medcanica, LLC. The portfolio consists of 14 U.S. issued patents, 4 non-U.S. patents, and 1 U.S. patent application.

17 Feb 2010

Directing gold nanoparticles into nucleus can kill cancer cells

Taking gold nanoparticles to the cancer cell and hitting them with a laser has been shown to be a promising tool in fighting cancer, but what about cancers that occur in places where a laser light can't reach? Scientists at the Georgia Institute of Technology have shown that by directing gold nanoparticles into the nuclei of cancer cells, they can not only prevent them from multiplying, but can kill them where they lurk. The research appeared as a communication in the February 10 edition of the Journal of the American Chemical Society.

17 Feb 2010

Patients and doctors differ when it comes to daily health activities

When it comes to daily health activities such as diet and exercise, Americans and their doctors may not always see eye to eye.

17 Feb 2010

New book by 12 world-leading scientists calls for renewed approach to drug policy

Drug policy - or really, the way our society controls and provides interventions for both legal and illegal psychoactive substances - is one of those things that seems inherently controversial.

17 Feb 2010

Educational event: SCAI highlights gender and racial disparities in treating cardiovascular disease

The Society for Cardiovascular Angiography and Interventions (SCAI) today announced an educational event for the public highlighting the gender and racial disparities in the prevention and treatment of cardiovascular disease. The "Know What Counts" educational program titled, "The Path to Health Care Equity: Identifying and Solving Racial, Ethnic, and Gender Disparities in Health Care in the New Century," will feature a distinguished physician panel, along with a keynote address by U.S. Senator Ben Cardin.

17 Feb 2010

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).

17 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Medical News

UKONS publishes position statement on safe, effective use of oral anticancer medicines

OTRC: Secondhand smoke exposure is a serious health hazard

AHF to protest Merck’s Isentress pricing and policies at CROI

Purdue officials report double-digit increases in research funding

CDA, OneAmerica Financial Partners to educate American workforce on disability planning

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Low-income nations lack advanced e-health tools that can help them achieve better health outcomes

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

Novel composite foam could lead to new generation of biomedical implants

LUMEDX completes extensive cardiovascular PACS deployment at IHS

Researchers find food safety violations in independently owned ethnic restaurants in Kansas

AMAG's Feraheme use on the rise

Researchers discover new strategy to overcome drug resistance in breast cancer

ICAP Ocean Tomo offers Medcanica's patent portfolio for sale

Directing gold nanoparticles into nucleus can kill cancer cells

Patients and doctors differ when it comes to daily health activities

New book by 12 world-leading scientists calls for renewed approach to drug policy

Educational event: SCAI highlights gender and racial disparities in treating cardiovascular disease

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News